ARTICLE | Emerging Company Profile
Dual: Multi-pronged attack
Dual developing PP2A activators to disrupt multiple cancer-associated pathways
June 23, 2014 7:00 AM UTC
Dual Therapeutics LLC is developing first-in-class oral small molecules that directly activate protein phosphatase 2 to disrupt multiple cancer pathways simultaneously. By restoring the phosphatase's activity to normal levels, the approach could treat prostate cancers that are resistant to anti-androgens and chemotherapy.
Protein phosphatase 2 (PPP2CA; PP2A) is a serine/threonine phosphatase that is a tumor suppressor. It is down-regulated in various cancers...